Estados Unidos · Plataformas y datos · MarketBeat

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

Publicado por MarketBeat · Estados Unidos hace 1 h

ProKidney (NASDAQ:PROK) said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

También te puede interesar

Can nVent Electric Become the Next Vertiv?

The real way to tell if Amazon’s AI spending is paying off

Top Performing Defensive Stocks

Earnings call transcript: Nebras Energy tops revenue estimates in Q3 2026

Gen Korean BBQ’s next chapter comes with wagyu, buffets and new names

Novartis Raises Guidance After Trial Setbacks Hit Profit

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

Compartir

También te puede interesar

Can nVent Electric Become the Next Vertiv?

The real way to tell if Amazon’s AI spending is paying off

Top Performing Defensive Stocks

Earnings call transcript: Nebras Energy tops revenue estimates in Q3 2026

Gen Korean BBQ’s next chapter comes with wagyu, buffets and new names

Novartis Raises Guidance After Trial Setbacks Hit Profit